This database contains 211 studies, archived under the term: "Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime"
Click here to filter this large number of results.
Concentration of donepezil to the cognitive response in Alzheimer disease
Yang, Yuan-Han,
Chen, Chun-Hung,
Chou, Mei-Chuan,
Li, Chien-Hsun,
Liu, Ching-Kuan,
Chen, Su-Hwei
Background: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration.; Methods: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains […]
The long-term efficacy and tolerability of donepezil in patients with vascular dementia
Wilkinson, David,
Róman, Gustavo,
Salloway, Stephen,
Hecker, Jane,
Boundy, Karyn,
Kumar, Dinesh,
Posner, Holly,
Schindler, Rachel
Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD).; Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer’s […]
Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
Background: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer’s disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. Methods: Six hundred and eighty-one deceased patients with a clinical […]
Memantine in behavioral variant frontotemporal dementia: negative results
Vercelletto, Martine,
Boutoleau-Bretonnière, Claire,
Volteau, Christelle,
Puel, Michèle,
Auriacombe, Sophie,
Sarazin, Marie,
Michel, Bernard-François,
Couratier, Philippe,
Thomas-Antérion, Catherine,
Verpillat, Patrice,
Gabelle, Audrey,
Golfier, Véronique,
Cerato, Evelyne,
Lacomblez, Lucette
We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician’s Interview-Based […]
EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study
Vellas, B.,
Sol, O.,
Snyder, P. J.,
Ousset, P. J.,
Haddad, R.,
Maurin, M.,
Lemarié, J. C.,
Désiré, L.,
Pando, M. P.
Background: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer’s Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.; Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in […]
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
Taipale, Heidi,
Tanskanen, Antti,
Koponen, Marjaana,
Tolppanen, Anna-Maija,
Tiihonen, Jari,
Hartikainen, Sirpa
The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the […]
Rivastigmine patch ameliorates depression in mild AD: Preliminary evidence from a 6-month open-label observational study
Spalletta, Gianfranco,
Gianni, Walter,
Giubilei, Franco,
Casini, Anna R.,
Sancesario, Giuseppe,
Caltagirone, Carlo,
Cravello, Luca
Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer’s Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n = 50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE […]